Execs On The Move: Management Changes At Sphingotec And Rockwell Medical; New Chair At Orexo
Executive Summary
A new COO joined the management team at German biomarker company Sphingotec; Rockwell Medical, a producer of kidney disease therapies, picks a CEO; Orexo AB, a developer of proprietary drug delivery technology, gets new board chair; and more.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.